BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 20/04/2016

Comparability Protocols for Human Drugs and Biologics: Chemistry, Manufacturing, and Controls Information; Draft Guidance for Industry; Availability

The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled "Comparability Protocols for Human Drugs and Biologics: Chemistry, Manufacturing, and Controls Information." This document is a revised version of a draft guidance that published in February 2003 entitled "Comparability Protocols: Chemistry, Manufacturing, and Controls Information." A related draft guidance entitled "Comparability Protocols--Protein Drug Products and Biological Products--Chemistry, Manufacturing, and Controls Information," that published in September 2003, was withdrawn on May 6, 2015. The revised draft guidance provides recommendations to human drug and biologics manufacturers on implementing a chemistry, manufacturing, and controls (CMC) postapproval change(s) through the use of a comparability protocol (CP). By using a CP, manufacturers who fall within the scope of this guidance will not have to submit commercial- scale CMC information on postchange products to FDA before making the proposed change. This draft guidance is intended to establish a framework to promote manufacturing of quality drug products.

Source: Federal Register — Food and Drug AdministrationOpen original release →